212 related articles for article (PubMed ID: 17869670)
1. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
[TBL] [Abstract][Full Text] [Related]
2. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
[TBL] [Abstract][Full Text] [Related]
3. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
[TBL] [Abstract][Full Text] [Related]
5. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
[TBL] [Abstract][Full Text] [Related]
8. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
9. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
Heyerdahl H; Røe K; Brevik EM; Dahle J
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):153-9. PubMed ID: 23790511
[TBL] [Abstract][Full Text] [Related]
10. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
Andersson H; Elgqvist J; Horvath G; Hultborn R; Jacobsson L; Jensen H; Karlsson B; Lindegren S; Palm S
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
14. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
[TBL] [Abstract][Full Text] [Related]
15. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
[TBL] [Abstract][Full Text] [Related]
16. Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.
Larsen RH; Hoff P; Vergote IB; Bruland OS; Aas M; De Vos L; Nustad K
Gynecol Oncol; 1995 Apr; 57(1):9-15. PubMed ID: 7705707
[TBL] [Abstract][Full Text] [Related]
17. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities.
Elgqvist J; Andersson H; Haglund E; Jensen H; Kahu H; Lindegren S; Warnhammar E; Hultborn R
Cancer Biother Radiopharm; 2009 Aug; 24(4):509-13. PubMed ID: 19694586
[TBL] [Abstract][Full Text] [Related]
19. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
Akabani G; Carlin S; Welsh P; Zalutsky MR
Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
